Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2024 06:59 ET | Source: Pasithea

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea to present preclinical data at ASCO 2024 showing PAS-004 superior inhibition of NRAS cancer cells and xenograft tumors compared to current MEKi's
November 19, 2021 05:03 ET | Source: Research and Markets

Global MEK Inhibitors Market, Drug Sales & Clinical Trials to 2026: USD 3 Billion Market Opportunity

Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026" report has been added to ResearchAndMarkets.com's offering. The advances...
November 09, 2021 06:03 ET | Source: Research and Markets

RAS Targeting Therapies Market, 2031

Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...